SUPPORTING INFORMATION

Syntesis and pharmacological characterization of conformationally restricted retigabine analogues as novel neuronal Kv7 channels activators

Carmine Ostacolo,^{†,#} Francesco Miceli^{¶,#}, Veronica Di Sarno^{‡,#}, Piera Nappi[¶], Nunzio Iraci[‡], Maria Virginia Soldovieri[§], Tania Ciaglia[‡], Paolo Ambrosino[¥], Vincenzo Vestuto[‡], Anna Lauritano[¶], Simona Musella[⊥], Giacomo Pepe[‡], Manuela G. Basilicata[‡], Michele Manfra[†], Diego Romano Perinelli[□], Ettore Novellino[†], Alessia Bertamino[‡], Isabel M. Gomez-Monterrey[†], Pietro Campiglia^{‡,*}, Maurizio Taglialatela^{¶,*}

† Department of Pharmacy, University Federico II of Naples, Via D. Montesano 49, 80131, Naples, Italy

Department of Neuroscience, Reproductive Sciences and Dentistry, University Federico II of Naples, Via Pansini, 5, 80131, Naples, Italy

‡ Department of Pharmacy, University of Salerno, Via G. Paolo II 132, 84084, Fisciano, Salerno, Italy

\$Department of Medicine and Health Science V. Tiberio, University of Molise, Via F. de Sanctis, 86100, Campobasso, Italy

¥ Department of Science and Technology (DST), University of Sannio, Via Port'Arsa 11, 82100, Benevento Italy;

^T Department of Science, University of Basilicata, Via dell'Ateneo Lucano 10, 85100 Potenza, Italy

^{II} School of Pharmacy, University of Camerino, Via Gentile III da Varano, 62032, Camerino (MC), Italy

L European Biomedical Research Center (EBRIS), Via Salvatore de Renzi, 3, 84125 Salerno (SA), Italy

Table of content:

1.		v	mes and fig		the rotati	on of the bond c	connecting th	a hydrogan
	bond	-	group	-			-	
						e electron densit		
						ed currents of Ky		
			-		-	and retigabine usi		
	probe							S10
	Figure S3	. Effect of r	etigabine and	d 23a on	Kv7.1 ch	annels		
	Figure S4	. Superimpo	osition of mo	dels B an	d C			<i>S11</i>
	Table S3.	Training se	ets of models	s A, B ar	nd C. Act	ive compounds a	are typed in g	green, while
	inactive or	nes are in re	d					S12
	Figure S5	. UHPLC p	rofile of a re	tigabine l	oatch afte	r 6h visible light	irradiation	<i>S13</i>
	Figure S	6. Full sc	an profile,	MS/MS	profile	and predicted	structure of	retigabine
						spectra of the m		
						enzaldehyde and		
	0	-				#1 and putative n		
	0		,	· •		poud 8a after the		
	Figure S1	1. Blank RI	P-HPLC trace	e of the n	nethod use	ed for purity dete	rmination of	compounds
						24a-b, 25a-29a		
	-				•	method used for		
	compound	s 33a and 3	33b .					S20

2.	NMR	spectra	and	HPLC	traces	of	synthesized
	compounds.						

1. Supplementary schemes and figures:




Figure S1. Relative potential energies for the rotation of the bond connecting the hydrogen bond donor group to the hydrogen bond acceptor one, according to the OPLS3 forcefield. Scanned dihedral angles are red-highlighted in the legend. *For these molecules, due to the presence of a second NH group, a two-coordinate scan was employed. (see materials and methods)




Table S1. Linker moieties connecting the 5-amino group to R1 group. ^aRelative electrostatic potential surfaces. Relative potentials are color coded by a red-white-blue color ramp, from the most negative to the most positive value. ^bRelative electron densities surfaces. Relative densities are color coded by a red-white-blue color ramp, from to lowest to the highest electron density.

NAME	STRUCTURE	I _{drug} /I _{cil} at -40 mV	Idrug/Ictl at 0 mV	N
Flupirtine	NH NH2	2.47±0.23	1.24±0.08	5
ICA27243		8.97±0.89	2.84±0.34	5
Retigabine (1 µM)	HN F	3.96±0.51	1.82±0.16	11
Flupirtine	NH NH NH2	2.47±0.23	1.24±0.08	5
Retigabine	HN F	6.20±1.03	1.95±0.12	38
4a	F (C) + F (C)	2.01±0.58	1.26±0.13	6
4b		0.80±0.14	0.48±0.07	5
5a	F-C	3.31±0.61	1.40±0.08	6
5b	HZ P P	0.91±0.21	0.81±0.11	5
6	F-C-H-H-K N-S-K-K	1.77±0.77	1.04±0.24	3
7		0.98±0.09	0.84±0.09	3

8a	F-C-	6.41±0.93	2.81±0.26	9
8b	F C F	1.15±0.28	0.64±0.14	3
8c	F-C	2.03±0.19	1.55±0.12	5
8d	HZ OO	2.55±0.79	1.93±0.32	5
8e	F	2.48±0.20	2.18±0.09	3
8f	F-C)-H	1.12±0.05	0.99±0.06	3
8g	F	1.49±0.28	1.16±0.07	5
8h	F-C)-N-C-N-C-N-C-N-C-N-C-N-C-N-C-N-C-N-C-	0.89±0.12	0.98±0.11	5

8i	F-Cy-N-S-S-N-C	1.91±0.44	1.87±0.22	5
9a	F-C	1.88±0.14	1.64±0.20	4
9b	F C F	1.32±0.21	0.66±0.07	5
9с		2.37±0.40	1.71±0.12	4
13a	F N S O	5.82±1.38	3.79±1.09	3
13b	F N N N N N N N N N N N N N N N N N N N	4.56±1.11	2.11±0.18	3
13c	F ₃ C-C	3.62±0.20	2.37±0.58	3

13d		6.43±1.51	4.24±0.83	3
13e	CF3 N N N N N N N N N N N N N N N N N N N	1.53±0.39	1.22±0.11	5
13f	TZ O	1.13±0.15	0.92±0.13	3
13g		7.27±1.32	3.09±0.52	4
16a	F C C C C C C C C C C C C C C C C C C C	1.85±0.30	1.22±0.07	4
16b		1.45±0.08	1.18±0.08	3
19	N T S O	3.24±1.52	1.37±0.17	4

23a	F ₃ C-C	9.34±0.82	3.24±0.18	5
23b	o-o-C	6.31±1.89	2.20±0.12	4
23c	F C Y	4.71±1.31	2.76±0.19	7
23d	0-()-()-()-()-()-()-()-()-()-()-()-()-()-	2.00±0.36	1.63±0.06	4
24a	F ₃ C	8.23±1.36	3.54±0.88	3
24b	HO	4.50±1.20	2.72±0.92	4
25a	F ₃ C-()+	1.29±0.18	1.02±0.05	3

26a	F ₃ C-C	2.27±0.49	1.93±0.19	3
27a	F-C	0.94±0.16	0.8±0.13	3
28a	F ₃ C	1.31±0.22	1.10±0.04	4
29a	F ₃ C	1.60±0.30	1.30±0.11	4
33a	H CF ₃	1.90±0.40	1.43±0.16	3
33b	F ₃ C	1.34±0.47	0.95±0.15	3
34	F ₃ C	1.67±0.18	1.04±0.05	3




Figure S2. Fluorescence intensity ratio at two different wavelengths (I=372 nm and III=383 nm) for **23a**, **24a** and retigabine using pyrene as fluorescent probe.




Figure S3. Effect of retigabine and 23a on homomeric Kv7.1 channels




Figure S4. Superimposition of models B (solid spheres) and C (transparent spheres). Pharmacophore features are color-coded as follows: Hydrophobic (HY – cyan), Aromatic (Ar – orange), Hydrogen Bond Donor (HBD – green), Hydrogen Bond Donor (HBD – green). Retigabine is depicted in green sticks as reference.

Molecule	Model A	Model B	Model C
8 a	X		X
13 a	Χ		Χ
13b	Χ		Χ
13d	Χ		Χ
13g	Χ		X
23a	Χ	Χ	
23c	Χ		Χ
24 a	Χ	Χ	
Retigabine	Χ	Χ	
23b	Χ	Χ	X
24b	Χ	Χ	Χ
25 a	Χ	Χ	Χ
27a	Χ	Χ	Χ
28a	Χ	Χ	Χ
29a	Χ	Χ	Χ
33 a	Χ	Χ	Χ
33 b	Χ	Χ	Χ
34	Χ	Χ	Χ

Table S3. Training sets of models A, B and C. Active compounds are typed in green, while inactive ones are in red. Crosses indicate whether the compound was used for a model or not.




Figure S5. UHPLC profile of a retigabine batch after 6h visible light irradiation




Figure S6. Full scan profile (A), MS/MS profile (B) and predicted structure of retigabine photoxidative byproduct eluting at 14.23 minutes (C).




Figure S7. (A) Retigabine GC profile and (B) full scan mass spectra of the main peak (4-fluorobenzaldehyde)




Figure S8. Overlapping HPLC traces of a 4-fluorobenzaldehyde standard solution and a photodegraded retigabine batch




Figure S9. MS/MS profile for unknown compound #1 and the corresponding putative molecular structures




Figure S10. HPLC (A), GC (B) and MS (C) profile for compoud 8a after the photodegradation assay




Figure S11. Blank RP-HPLC trace of the analytical method used for purity determination of compounds 4a-b, 5a-b, 6-7, 8a-i, 9a-c, 13a-g, 16a-b, 19, 23a-d, 24a-b, 25a-29a and 34






Figure S12. Blank RP-HPLC trace for the analytical method used for purity determination of compounds 33a and 33b.


2. NMR spectra and HPLC traces of synthesized compounds




1H NMR of compound 4a




13C NMR of compound 4a




RP-HPLC trace of compound 4a




1H NMR of compound 4b




13C NMR of compound **4b**




RP-HPLC tracce of compound **4b**




1H NMR of compound **5a**




13C NMR of compound 5a




RP-HPLC trace of compound **5a**




1H NMR of compound **5b**




13C NMR of compound **5b**




RP-HPLC trace of compound **5b**







13C NMR of compound 6




RP-HPLC trace of compound **6**




1H NMR of compound 7




13C NMR of compound 7




RP-HPLC trace of compound 7




1H NMR of compound 8a







RP-HPLC trace of compound 8a




1H NMR of compound **8b**




S43




RP-HPLC trace of compound **8b**




1H NMR of compound 8c




13C NMR of compound 8c




RP-HPLC trace of compound 8c







13C NMR of compound 8d




RP-HPLC trace of compound 8d




1H NMR of compound 8e




13C NMR of compound 8e




RP-HPLC trace of compound **8e**







13C NMR of compound 8f




RP-HPLC of compound 8f




1H NMR of compound 8g







RP-HPLC trace of compound 8g




1H NMR of compound 8h




13C NMR of compound **8h**




RP-HPLC trace of compound 8h









S64




RP-HPLC of compound 8i




S66







RP-HPLC of compound 9a




S69




S70




RP-HPLC trace of compound **9b**







S73




RP-HPLC trace of compound 9c








S76




RP-HPLC trace of compound **13a**









RP-HPLC trace of compound **13b**







S82




1H NMR of compound **13c**




S84







RP-HPLC trace of compound 13d




1H NMR of compound **13e**




S88




RP-HPLC of compound 13e




S90




S91




RP-HPLC of compound 13f













RP-HPLC trace of compound 13g







13C NMR of compound 16a







S99






RP-HPLC trace of compound **16b**







S103




RP-HPLC trace of compound **19**




1H NMR of compound 23a




S106




RP-HPLC of compound 23a







S109





RP-HPLC trace of compound 23b




S111













S115




RP-HPLC trace of compound 23d










RP-HPLC trace of compound **24a**










RP-HPLC of compound **24b**












1H NMR of compound **26a**









RP-HPLC trace of compound **26a**




S129







S131




S132





S133




RP-HPLC trace of compound 28a










S137









HMBC NMR spectra of compound 33a




HMQC NMR spectra of compound 33a




ROESY NMR spectra of compound 33a




RP-HPLC trace of compound **33a**







qDEPT NMR of compound 33b




HMBC NMR spectra of compound **33b**





HMQC NMR spectra of compound 33b




ROESY NMR spectra of compound 33b









RP-HPLC trace of compound 34